



Correction: End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics

Annette Medina Morales¹ · Alavattam Sreedhara² · Jakob Buecheler³ · Sebastian Brosig³ · Danny Chou⁴ · Twinkle Christian⁵ · Tapan Das⁶ · Isabella de Jong² · Jonas Fast⁷ · Bharat Jagannathan⁵ · Ehab M. Moussa⁸ · M. Reza Nejadnik⁹ · Indira Prajapati¹ · Allison Radwick¹⁰ · Yusra Rahman⁹ · Shubhadra Singh¹¹

Published online: 11 January 2023

© The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2023

<https://doi.org/10.1208/s12248-022-00773-3>

The original article has been updated to correct the order of authors.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1208/s12248-022-00773-3>.

✉ Annette Medina Morales
annette.medina@astrazeneca.com

¹ Dosage Form Design and Development, BioPharmaceuticals Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD 20878, USA

² Genentech, Pharmaceutical Development, South San Francisco, CA 94080, USA

³ Technical Research Development, Novartis Pharma AG, 4002 Basel, Switzerland

⁴ Compassion BioSolution, LLC, Lomita, CA 90717, USA

⁵ Amgen, Process Development, Thousand Oaks, CA 91320, USA

⁶ Analytical Development and Attribute Sciences, Bristol Myers Squibb, New Brunswick, NJ, USA

⁷ Pharmaceutical Development, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland

⁸ Drug Product Development, AbbVie, North Chicago, IL 60064, USA

⁹ Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA

¹⁰ Symbiotix, New York City, NY 10016, USA

¹¹ GlaxoSmithKline R&D, Biopharmaceutical Product Sciences, Collegeville, Philadelphia, PA 19426, USA